Hypoparathyroidism (HypoPT) is characterized by low serum calcium levels caused by an insufficient secretion of parathyroid hormone (PTH). Despite normalization of serum calcium levels by treatment with activated vitamin D analogues and calcium supplementation, patients are suffering from impaired quality of life (QoL) and are at increased risk of a number of comorbidities. Thus, despite normalization of calcium levels in response to conventional therapy, this should only be considered as an apparent normalization, as patients are suffering from a number of complications and calcium-phosphate homeostasis is not normalized in a physiological manner. In a number of recent studies, replacement therapy with recombinant human PTH (rhPTH(1-84)) as well as therapy with the N-terminal PTH fragment (rhPTH(1-34)) have been investigated. Both drugs have been shown to normalize serum calcium while reducing needs for activated vitamin D and calcium supplements. However, once a day injections cause large fluctuations in serum calcium. Twice a day injections diminish fluctuations, but don't restore the normal physiology of calcium homeostasis. Recent studies using pump-delivery have shown promising results on maintaining normocalcemia with minimal fluctuations in calcium levels. Further studies are needed to determine whether this may improve QoL and lower risk of complications. Such data are needed before replacement with the missing hormone can be recommended as standard therapy.

Citations

Citations to this article as recorded by  

• Point-of-Care Peptide Hormone Production Enabled by Cell-Free Protein Synthesis
  Madison A. DeWinter, Ariel Helms Thames, Laura Guerrero, Weston Kightlinger, Ashty S. Karim, Michael C. Jewett
  ACS Synthetic Biology.2023; 12(4): 1216.     CrossRef
• Effects of Multi-stage Procurement on the Viability and Function of Human Donor Parathyroid Glands
  Yvonne M. Kelly, Casey Ward, Run Zhang, Shareef Syed, Peter G. Stock, Quan-Yang Duh, Julie A. Sosa, James Koh
  Journal of Surgical Research.2022; 276: 404.     CrossRef
• Kidney Complications and Hospitalization in Patients With Chronic Hypoparathyroidism: A Cohort Study in Sweden
  Oskar Swartling, Marie Evans, Tim Spelman, Wafa Kamal, Olle Kämpe, Michael Mannstadt, Ylva Trolle Lagerros, Sigridur Björnsdottir
  The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4098.     CrossRef
• Hypocalcaemia
  Zaki Hassan-Smith, Neil Gittoes
  Medicine.2021; 49(9): 562.     CrossRef
• Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism
  Michael Mannstadt, Bart L Clarke, John P Bilezikian, Henry Bone, Douglas Denham, Michael A Levine, Munro Peacock, Jeffrey Rothman, Dolores M Shoback, Mark L Warren, Nelson B Watts, Hak-Myung Lee, Nicole Sherry, Tamara J Vokes
  The Journal of Clinical Endocrinology & Metabolism.2019; 104(11): 5136.     CrossRef
• Management of Endocrine Emergencies in the ICU
  Judith Jacobi
  Journal of Pharmacy Practice.2019; 32(3): 314.     CrossRef
• Microencapsulated parathyroid allotransplantation in the omental tissue
  Emrah Yucesan, Harun Basoglu, Beyza Goncu, Fahri Akbas, Yeliz Emine Ersoy, Erhan Aysan
  Artificial Organs.2019; 43(10): 1022.     CrossRef
• Die HypAus-Studie
  Maximilian Zach, Adelina Tmava-Berisha, Stefan Schatzl, Michael Lehner, Greisa Vila, Karin Amrein
  Journal für Klinische Endokrinologie und Stoffwechsel.2018; 11(2): 45.     CrossRef
• Sustained release of parathyroid hormone via in situ cross‐linking gelatin hydrogels improves the therapeutic potential of tonsil‐derived mesenchymal stem cells for hypoparathyroidism
  Yoon Shin Park, Yunki Lee, Yoon Mi Jin, Gyungah Kim, Sung Chul Jung, Yoon Jeong Park, Ki Dong Park, Inho Jo
  Journal of Tissue Engineering and Regenerative Medicine.2018;[Epub]     CrossRef
• Hypocalcaemia
  Zaki Hassan-Smith, Neil Gittoes
  Medicine.2017; 45(9): 555.     CrossRef